No CrossRef data available.
Article contents
P01-48 - Haloperiol is a Better Choice than Risperidone for Patients with Schizopherenia with Positive Familial History
Published online by Cambridge University Press: 17 April 2020
Abstract
Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure that affects about 1.1 percent of the world population. But is there any difference for treating schizophrenia due to its cause? In this study we evaluate the therapeutic effect of haloperidol and risperidone in patients with positive familial history.
We had chosen 110 men with schizophrenia with positive familial history, who refer to psychology institute of Rasul Hospital in Tehran in 2000 to 2009. We divided these patients into two main groups by random, each group have 55 patients. For case group Haloperidol was used to control their symptoms and for the control group risperidone was used. During a period of one year we evaluate their response to the treatment in different groups.
The mean age of patients in case group was 34.8 and for control group it was 34.4. From the case group 45.2% show decrease in their symptoms and in control group just 36.6% so the therapeutic effect of haloperidol was significantly better than risperidon for patients who have positive familial history. In addition after 6 months of therapy just 12% of patient in case group have remission but is control group we faced 28.3%.
It is better to use the first line anti psychotic, haloperidol, in patients with positive familial history. This help to more decrease in symptoms and also the less chance for remission.
- Type
- Affective disorders / Unipolar depression / Bipolar disorder
- Information
- Copyright
- Copyright © European Psychiatric Association 2010
Comments
No Comments have been published for this article.